Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine 0.05% vs Artificial Tears in MGD
NCT00705510Phase 4Completed
- Sponsor
- Mahidol University
- Start
- May 2008
- Primary completion
- Oct 2010
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of cyclosporine ophthalmic solution in meibomian gland dysfunction (MGD) (2 arms), sponsored by Mahidol University. Primary endpoint: Non-invasive Tear Break Up Time at 3 months. Started May 2008; status: completed.
02
Drugs
cyclosporine ophthalmic solution
03
Conditions
meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on NCT00705510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00705510.